|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
15 January 2024 |
|
Main ID: |
NCT01765140 |
|
Date of registration:
|
06/01/2013 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Treatment Use of 3,4-Diaminopyridine
|
|
Scientific title:
|
Treatment Use of 3,4-Diaminopyridine in Congenital Myasthenic Syndrome |
|
Date of first enrolment:
|
December 2012 |
|
Target sample size:
|
|
|
Recruitment status: |
No longer available |
|
URL:
|
https://clinicaltrials.gov/ct2/show/NCT01765140 |
|
Study type:
|
Expanded Access |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Vern C. Juel, M.D. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Duke University |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Diagnosis of congenital myasthenic syndrome (CMS)
- Women of childbearing potential must have negative pregnancy test and agree to
practice adequate contraception while taking DAP
- Must be competent to give consent
Exclusion Criteria:
- Known seizure disorder
- Pregnancy
- Known cardiac arrhythmia or evidence of significant arrhythmia on screening ECG
- Known hepatic, renal or hematologic disease
Age minimum:
N/A
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Myasthenic Syndromes, Congenital
|
|
Intervention(s)
|
|
Drug: 3,4-diaminopyridine
|
|
Secondary ID(s)
|
|
Pro00007811
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|